FDA Mandates New Labeling for Testosterone Products Over Blood Pressure Concerns

The U.S. Food and Drug Administration has mandated new labeling updates for testosterone products following a series of clinical and post-market studies. The revised labels reflect findings from a major clinical trial that examined the cardiovascular safety of testosterone replacement therapy in men with hypogonadism. Although the trial did not show an increased risk of adverse cardiovascular events, additional research using ambulatory blood pressure monitoring revealed that testosterone use may lead to elevated blood pressure levels.

In response, the FDA now requires manufacturers to update their product labels to include warnings about potential increases in blood pressure. Testosterone therapies, which are approved for men with medically low testosterone levels, are available in several formulations including oral tablets, topical gels, transdermal patches, and injections. The agency stated that these changes are intended to ensure that both healthcare providers and patients receive clear and comprehensive safety information regarding the use of testosterone treatments.